Arovella Therapeutics Limited (ALA)

Overview

Arovella Therapeutics Limited is an innovative biotechnology firm with a focused mission on creating novel therapies to combat cancer and disorders impacting the central nervous system. Operating on a global scale with roots in Australia, Arovella leverages cutting-edge science and strategic partnerships to push the boundaries of medical science. The company, originally known as Suda Pharmaceuticals Ltd, embraced a new identity as Arovella Therapeutics Limited in October 2021 to better reflect its expanding portfolio and ambition. Since its establishment in 1999, Arovella has been steadfast in its commitment to addressing some of the most challenging health concerns facing the world today. Its collaboration with renown institutions like Imperial College London illustrates Arovella's dedication to excellence and innovation in research. Based in Preston, Australia, Arovella Therapeutics is poised at the forefront of biotechnological advancements.

Products and Services

• ZolpiMist - An orally administered spray containing zolpidem tartrate, ZolpiMist is Arovella's answer to treating insomnia. The active ingredient, zolpidem tartrate, is also known by the brand names Ambien or Stilnox, depending on the market. This product stands out due to its innovative delivery system, offering a convenient and effective solution for those struggling with sleep disorders.
• Invariant Natural Killer T (iNKT) Cell Therapy Platform - A pioneering approach in the fight against blood cancer, Arovella's iNKT cell therapy platform showcases the company's commitment to developing treatments that harness the body's immune system. This cell therapy represents a significant advancement in cancer treatment, targeting blood malignancies with the potential to revolutionize how these diseases are treated in the future.